Eager to redeem its Covid-19 vaccine, AstraZeneca touts 82.4% efficacy for 12-week dosing schedule — but will the FDA buy it?
AstraZeneca and Oxford say they now have clinical evidence that dosing their adenovirus-based Covid-19 vaccine 12 weeks apart — a regimen approved by the UK, perplexing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.